

BILH Interim COVID-19 Vaccine Clinics Guidance for 1st Dose Received Elsewhere

Please note that this guidance is only for when patients have arrived to the vaccine clinic. Patients are instructed not to schedule second dose appointment with BILH if they received their first dose elsewhere.

If a patient has arrived but received their first dose somewhere that is not a BILH site, please follow the guidance below. Refer to the following scenarios on how to deal with these circumstances, including CDC guidance for if the patient has no documentation/can't remember their first dose vaccine brand:

1. KNOWS vaccine brand:

1. At check-in:
 - a. Ask for vaccine brand of first dose (this should be provided by the CDC card) to ensure location has correct brand available
 - b. If incorrect brand, direct to <https://vaxfinder.mass.gov/> to reschedule to proper state location
 - c. If does not know vaccine brand, skip to **Section 2 below**.
 - d. If vaccine brand correct for location, in COVAX select walk-in under 1st dose
 - e. Click dropdown: **Administered at: Select Location**
 - f. Select option: **Outside BILH**

2. Proceed to **Section 3 below**

2. DOES NOT KNOW vaccine brand:

1. This should be only in **exceptional situations** where they cannot determine first dose brand ([see CDC guidance below](#))
2. Ask patient when they received their first dose
 - a. If it is <28 days since their first dose, instruct patient to schedule second dose for 28 days later at a state vaccination site **OR**
 - b. If it has been at least 28 days since their first dose, they may continue on to receive their second dose at BILH
3. At Check-In, in COVAX select walk-in under 1st dose
 - a. Click dropdown: **Administered at: Select Location**
 - b. Select option: **Outside BILH**

4. Proceed to **Section 3 below**

3. Vaccine administration documentation:

1. At the time of vaccine administration please enter the following into the required fields:
 - a. **Vaccine Name:** If known choose the appropriate brand. If brand is unknown, choose "unknown" as an option in the rare case someone doesn't know
 - b. **Date:** Add 1st dose vaccination date given per patient. If date is unknown, enter the date 28 days prior to the current date.
 - c. **Route:** IM
 - d. **Body Site:** Left Arm OR Right Arm

- e. **Lot #:** 111111
 - f. **Exp Date:** Enter the date immediately following the 1st dose vaccination date above
 - g. **Vaccinator Name:** Unknown
 - h. **Vaccinator Title:** Unknown
- 4. Second dose greater than 6 weeks post first dose:**
- a. If it has been longer than 6 weeks since first dose, clinics should attempt to give (or schedule at another site) the same brand as the first dose if possible. If that is not possible in a timely manner, any vaccine brand can be given.

[Go to next page](#)

WANG, ALLISON [REDACTED]

Destination Site: Boston

Patient Name DOB A
WANG, ALLIS... 5/25/1990 30

Home Address [REDACTED]

Demographic Information [REDACTED]

Cell Phone [REDACTED] Update

Language English

Email aswang@bidmc.harvard.edu Update

Dose 1

Checked in
 Walk-in

Administered at: Select a location

Dose 2

Checked in
 Walk-in

Save Dose 2

Save Dose 1

WANG, ALLISON [REDACTED]

Destination Site: Boston

Patient Name DOB A
WANG, ALLIS... 5/25/1990 30

Home Address [REDACTED]

Demographic Information [REDACTED]

Cell Phone [REDACTED]

Language English

Email aswang@bidmc.harvard.edu

Dose 1

Checked in
 Walk-in

Administered at: Select a location

Select a location
Beverly
Boston
Burlington
Cambridge
Chelsea
Dorchester
Gloucester
Lynnfield
Newburyport
North Quincy
Plymouth
Outside BILH

Dose 2

Checked in
 Walk-in

Save Dose 2

Save Dose 1

Vaccine Information

Vaccine Name: ✓

Date:

Route:

Body Site: Left Deltoid ▾

Not Administered
Pfizer
Moderna
Johnson & Johnson

Lot#:

Exp. Date: MM/DD/YY

Vaccinator Name:

Vaccinator Title:

Save Dose 1

*CDC Guidance (see appendix for full statement):

Interchangeability with other COVID-19 vaccine products:

- mRNA COVID-19 vaccines are not interchangeable with each other or with other COVID-19 vaccine products.
- In exceptional situations in which the first-dose vaccine product cannot be determined or is no longer available, any available mRNA COVID-19 vaccine may be administered at a minimum interval of 28 days between doses to complete the mRNA COVID-19 vaccination series. If two doses of different mRNA COVID-19 vaccine products are administered in these situations (or inadvertently), no additional doses of either product are recommended at this time.

[Go to next page](#)

Appendix

"Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines." Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. 5 March 2021.
www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html.

Interchangeability with other COVID-19 vaccine products:

Either of the currently authorized mRNA COVID-19 vaccines can be used when indicated; ACIP does not state a product preference. However, **these mRNA COVID-19 vaccines are not interchangeable with each other or with other COVID-19 vaccine products.** The safety and efficacy of a mixed-product series have not been evaluated. Both doses of the series should be completed with the same product.

Strategies to help ensure that patients receive the second dose with the appropriate product and interval between doses include:

- Providing COVID-19 vaccination record cards to vaccine recipients, asking recipients to bring their card to their appointment for the second dose, and encouraging recipients to make a backup copy (e.g., by taking a picture of the card on their phone).
- Encouraging vaccine recipients to enroll in VaxTextSM, a free text message-based platform to receive COVID-19 vaccination second-dose reminders.
- Recording each recipient's vaccination in the immunization information system (IIS).
- Recording vaccine administration information in the patient's medical record.
- Making an appointment for the second dose before the vaccine recipient leaves, to increase the likelihood that patients will present at the same vaccination site for the second dose.

Using the above strategies, every effort should be made to determine which vaccine product was received as the first dose, in order to ensure completion of the vaccine series with the same product. In exceptional situations in which the first-dose vaccine product cannot be determined or is no longer available, any available mRNA COVID-19 vaccine may be administered at a minimum interval of 28 days between doses to complete the mRNA COVID-19 vaccination series. If two doses of different mRNA COVID-19 vaccine products are administered in these situations (or inadvertently), no additional doses of either product are recommended at this time.

Recommendations may be updated as further information becomes available or other vaccine types (e.g., viral vector, protein subunit vaccines) are authorized.